IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Alembic is currently trading at Rs. 138.00, up by 6.05 points or 4.59% from its previous closing of Rs. 131.95 on the BSE. The scrip opened at Rs. 135.60 and has touched a high and low of Rs. 139.25 and Rs. 135.45 respectively. So far 26955 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 169.00 on 23-Aug-2024 and a 52 week low of Rs. 78.00 on 10-Nov-2023. Last one week high and low of the scrip stood at Rs. 139....
Alembic trades higher on reporting 50% rise in Q2 consolidated net profit
Indian drugmaker Alembic Pharmaceuticals reported a smaller-than-expected rise in second-quarter profit on Thursday, hurt by a slowdown in the U.S. market amid pricing pressure. The company's consolidated profit rose 12% to 1.53 billion rupees ($18.1 million) in the quarter ended Sept. 30, but fell short of the analysts' expectation of 1.55 billion rupees, per estimates compiled by LSEG. Revenue from operations, which rose 3.3% to 16.48 billion rupees, also missed analysts' ...
Indian drugmaker Alembic Pharma misses Q2 profit view as US sales growth slows
Alembic Pharmaceuticals is currently trading at Rs. 1177.95, up by 18.20 points or 1.57% from its previous closing of Rs. 1159.75 on the BSE. The scrip opened at Rs. 1160.05 and has touched a high and low of Rs. 1186.00 and Rs. 1160.05 respectively. So far 1003 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the ...
Alembic Pharma soars on getting USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
Alembic Pharmaceuticals is currently trading at Rs. 1245.00, up by 2.85 points or 0.23% from its previous closing of Rs. 1242.15 on the BSE. The scrip opened at Rs. 1259.65 and has touched a high and low of Rs. 1259.65 and Rs. 1217.05 respectively. So far 6937 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the s...
Alembic Pharmaceuticals inches up on getting final nod for Alcaftadine Ophthalmic Solution
Alembic Pharmaceuticals is currently trading at Rs. 1205.45, up by 12.80 points or 1.07% from its previous closing of Rs. 1192.65 on the BSE. The scrip opened at Rs. 1204.95 and has touched a high and low of Rs. 1248.95 and Rs. 1184.75 respectively. So far 28472 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the...
Alembic Pharmaceuticals surges after getting EIR from USFDA for Oral Solid Formulation Facility
Saksoft has acquired Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka. The company anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization. HDFC Life Insurance Company has received approval to raise funds up to Rs 1,500 c...
Saksoft, HDFC Life and Tata Motors to see some action today
Alembic Pharmaceuticals is currently trading at Rs. 1112.85, up by 12.30 points or 1.12% from its previous closing of Rs. 1100.55 on the BSE. The scrip opened at Rs. 1227.35 and has touched a high and low of Rs. 1227.35 and Rs. 1107.05 respectively. So far 15526 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the...
Alembic Pharmaceuticals gains on getting USFDA`s final approval for Betamethasone Valerate Foam
Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America. The company's consolidated net profit jumped nearly 31% year-on-year to 14.2 billion rupees ($169.2 million) in the quarter ended June 30, beat analysts' average estimate of 12.34 billion rupees, per LSEG data. KEY CONTEXT Indian generic drugmakers earn a major chunk of their revenue f...
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
Indian drugmaker Alembic Pharmaceuticals reported a 12% rise in first-quarter profit on Thursday, led by strong demand for its generic drugs in its key market of North America. The company's consolidated profit rose to 1.35 billion rupees ($16 million) for the quarter ended June 30, while revenue rose 5% to 15.62 billion rupees. Sales in the U.S. climbed 18%, pushing the market's contribution to Alembic's overall revenue to 29% from 26% a year ago. For further earni...
Indian drugmaker Alembic Pharma posts Q1 profit rise on strong US sales
Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection Aug-02-2024 12:16 Hrs IST Alembic Pharmaceuticals is currently trading at Rs. 1220.05, up by 4.45 points or 0.37% from its previous closing of Rs. 1215.60 on the BSE. The scrip opened at Rs. 1215.45 and has touched a high and low of Rs. 1231.25 and Rs. 1190.85 respectively. So far 9174 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has...
Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection
Alembic Pharmaceuticals is currently trading at Rs. 978.70, up by 4.80 points or 0.49% from its previous closing of Rs. 973.90 on the BSE. The scrip opened at Rs. 985.00 and has touched a high and low of Rs. 1005.10 and Rs. 964.85 respectively. So far 12484 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 641.65 on 14-Jul-2023. Last one week high and low of the scri...
Alembic Pharma gains on getting USFDA`s final approval for Bromfenac Ophthalmic Solution
Alembic Pharmaceuticals is currently trading at Rs. 988.80, up by 38.80 points or 4.08% from its previous closing of Rs. 950.00 on the BSE. The scrip opened at Rs. 970.00 and has touched a high and low of Rs. 990.00 and Rs. 955.10 respectively. So far 6489 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 635.00 on 05-Jul-2023. Last one week high and low of the scrip...
Alembic Pharma shines on getting USFDA`s tentative approval for Ivosidenib Tablets
Await US recovery and scale up; D/G to Reduce Result Synopsis Q4 turned out a weak revenue quarter but was saved by rather sharp uptick in gross margin QoQ. Company guided to 25 launches in current fiscal though no exclusivity products are lined up in the near term. India growth has been affected by weak acute season and presume current year to revert to normal demand for anti-infectives which would boost Azithromycin business. With no MR addition in domestic business and new facilities...
REDUCE Alembic Pharma Ltd. For Target Rs. 950 - Yes Securities
Exports drive earnings; weak show in DF segment Robust pace of launches to remain intact in US generics in FY25 * Alembic Pharma (ALPM) delivered better-than-expected 4QFY24 earnings, led by better gross margin and improved off-take in the API segment. After two consecutive years of weak financial performance, ALPM ended FY24 with 10%/14%/43% YoY growth in sales/EBIDTA/PAT to INR62b/INR9.3b/ INR6b. * We slightly raise our earnings estimates by 3%/2% for FY25/FY26, factoring in a hea...
Neutral Alembic Pharma Ltd. For Target Rs. 960 - Motilal Oswal Financial Services
Alembic Pharmaceuticals is currently trading at Rs. 894.90, up by 4.80 points or 0.54% from its previous closing of Rs. 890.10 on the BSE. The scrip opened at Rs. 905.00 and has touched a high and low of Rs. 917.50 and Rs. 891.75 respectively. So far 2464 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 600.65 on 23-Jun-2023. Last one week high and low of the scrip ...
Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection
Alembic Pharmaceuticals is currently trading at Rs. 959.35, up by 16.85 points or 1.79% from its previous closing of Rs. 942.50 on the BSE. The scrip opened at Rs. 942.50 and has touched a high and low of Rs. 960.00 and Rs. 936.70 respectively. So far 3793 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 542.40 on 31-May-2023. Last one week high and low of the scrip...
Alembic Pharma jumps on getting USFDA`s final nod for Sacubitril and Valsartan tablets
Work in progress for GLP-1 products Alembic Pharma (ALPM) delivered a better-than-expected operational performance in 3QFY24. A healthy show in formulation exports and the domestic formulation (DF) segment supported growth in sales/EBITDA. ALPM continued to improve the base of its US generics business. Robust demand led to strong off-take in non-US exports. We raise our earnings estimates by 2%/3%/4% for FY24/FY25/FY26 to factor in a) superior execution in animal healthcare segment, b) ...
Neutral Alembic Pharma Ltd For Target Rs.910 By Motilal Oswal Financial Services Ltd
Alembic Pharmaceuticals is currently trading at Rs. 1013.55, up by 8.70 points or 0.87% from its previous closing of Rs. 1004.85 on the BSE. The scrip opened at Rs. 1008.95 and has touched a high and low of Rs. 1035.00 and Rs. 1003.80 respectively. So far 3128 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 485.05 on 05-Apr-2023. Last one week high and low of the s...
Alembic Pharma rises on getting tentative USFDA`s nod for breast cancer drug
India's Alembic Pharmaceuticals reported a bigger-than-expected third-quarter profit on Monday, driven by higher sales in the domestic and U.S. markets. The generic drugmaker reported a consolidated net profit of 1.80 billion rupees (nearly $22 million) for the three months ending Dec. 31, beating analysts' average estimate of 1.46 billion rupees, as per LSEG data. It had reported a profit of 1.22 billion rupees in the year-ago period. New product launches and easing price erosi...
India`s Alembic Pharma beats Q3 profit view on strong domestic, US sales
US ramp up key to margin Result Synopsis US business clocked robust growth on back of buoyancy in existing business and moderate price erosion though muted India (actually flat YoY ex-animal health business) and higher opex due to full expensing of 3 facilities impacted margin. With some recovery in US, we would have expected better margin profile but for higher staff costs related to 3 new facilities. Management refrained from giving any margin/revenue guidance though it did reiterate ...
Add Alembic Pharmaceuticals Ltd For Target Rs.800 - Yes Securities
Steady quarter; margin recovery awaited ALPM’s 2Q revenue was in line with JMFe driven by non-US formulations. Domestic business dragged growth due to delayed acute season/ high base. New facility costs (c. INR 550mn) resulted in weaker EBITDA margin, leading to a 7% PAT miss. US performance was better than expectations as moderate price erosion, new launches and shortages benefited the company. As launches from new facilities ramp up, which could take a few quarters, we expect healt...
Buy Alembic Pharmaceuticals Ltd For Target Rs.915 - JM Financial Services
India's Alembic Pharmaceuticals on Tuesday reported second-quarter profit roughly in line with estimates, as higher sales in its domestic and overseas markets offset a jump in expenses. The generic drugmaker's consolidated net profit came in at 1.37 billion rupees ($16.5 million) for the quarter ended Sept. 30, up 3% from last year. It was largely in-line with analysts' estimate of 1.38 billion rupees as per LSEG data. Analysts expected generic drugmakers to benefit from ...
India's Alembic Pharma Q2 profit roughly in-line with estimates
Load More
